APOLLO BEACH, Fla., January 14, 2026 (GLOBE NEWSWIRE) —RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”) a company developing ultra-high-resolution retinal imaging technology, today announced that a recent large‑scale Australian retinal mapping study, which used artificial intelligence to analyze approximately 50,000 retinal scans, reported that specific patterns of retinal thinning are

Zwerling expected to guide the Company to its commercial launch.  APOLLO BEACH, Fla., December 8, 2025 (GLOBE NEWSWIRE) —RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”) a company developing ultra-high-resolution retinal imaging technology, combined with advanced genetic testing, today announced the signing of an agreement to hire M. Cory Zwerling

APOLLO BEACH, Fla., October 16, 2025 (GLOBE NEWSWIRE) —RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), RetinalGenix Technologies Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution retinal imaging technology, today announced it has engaged Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform

APOLLO BEACH, Fla., October 1, 2025 (GLOBE NEWSWIRE) —RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneering developmental-stage company focused on ophthalmic screening, monitoring, pharmacogenetic mapping, and repurposed drug development for early detection and treatment of eye and systemic diseases, and RGEN Inc., a leader in genetic research and innovation

APOLLO BEACH, Fla., September 25, 2025 (GLOBE NEWSWIRE) —RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), RetinalGenix Technologies Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), a pioneering developmental-stage ophthalmic monitoring and biopharmaceutical company focused on early detection and treatments for eye and systemic diseases, is proud to announce significant advancements in

Cost-Efficient Methodology Aims To Reduce Reliance On Expensive Diagnostic Procedures Such As MRI, CT Scans, PET Scans, and Echocardiograms APOLLO BEACH, Fla., June 27, 2025 (GLOBE NEWSWIRE) —RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), APOLLO BEACH, Fla., June 27, 2025 (GLOBE NEWSWIRE) —RetinalGenix TechnologiesInc. OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneering

Appointment Underscores RetinalGenix’s Commitment to Integrating the Latest Advances in genomics and personalized medicine into its product pipeline APOLLO BEACH, Fla., June 13, 2025 (GLOBE NEWSWIRE) —RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneer in advanced retinal imaging and precision medicine, is pleased to announce the appointment of

Company to use facility to further development of RetinalGenix’s therapies for neurodegenerative and retinal diseases APOLLO BEACH, Fla., May 5, 2025 (GLOBE NEWSWIRE) — RetinalGenix Technologies Inc   OTCQB:RTGN (“RetinalGenix” or the “Company”), announced today a new laboratory lease agreement with life science incubator MBC BioLabs for a brand new facility located in San

Company will discuss its patented remote monitoring high-resolution retinal imaging system RetinalCam™ and associated biomarker technologies APOLLO BEACH, Fla., March 6, 2025 (GLOBE NEWSWIRE) — RetinalGenix Technologies Inc   OTCQB:RTGN (“RetinalGenix” or the “Company”), today announced it will participate at the 37th Annual Roth Conference on March 16th to 18th. The Company will

High-Resolution Retinal Imaging Now Using Both Near Infrared And Green Modes APOLLO BEACH, Fla., Feb. 20, 2025 (GLOBE NEWSWIRE) — RetinalGenix Technologies Inc   OTCQB:RTGN (“RetinalGenix” or the “Company”), announced today that it has achieved an important milestone in developing its high-resolution retinal imaging device and remote monitoring system. The Company has successfully started

PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company’s System And Method For Visualization Of Ocular Anatomy. The present invention relates to systems

PETALUMA, Calif., December 26, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has contracted with MEDsan, Inc. (“MEDsan” to provide diagnostic testing services for its Institutional Review Board (IRB) to conduct a study to personalize medical evaluations for patients receiving treatment for

PETALUMA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) — RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Anatoly Dritschilo, M.D. has joined the Company’s Medical Advisory Board. RetinalGeniX is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging and

PETALUMA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) — RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Dessislava (Dessy) Boneva, M.D. has joined the Company’s Board of Directors. RetinalGeniX is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging

PETALUMA, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Stephen Tannenbaum to the Business Advisory Board of RetinalGeniX. Mr. Tannenbaum will provide strategic business advice, consult on potential mergers and acquisitions, and the development of channels to acquire

PETALUMA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has submitted two provisional patent applications to the US Patent Office for its investigational therapeutic drug candidates RTG-2023 and RTG-2024. RTG-2023 is being developed to treat dry age-related macular degeneration (AMD).

PETALUMA, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has contracted with Avania CRO to provide guidance for the Company’s interactions with the FDA for the development of [1] RTG-2023 for the treatment of dry age-related macular degeneration (dry

PETALUMA, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced the launch of an Institutional Review Board (“IRB”) for research on its DNA/GPS program. The study aims to offer recommendations for enhancing the preselection process and management of ocular injections. The proposed

PETALUMA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) — RetinalGeniX Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) released to the public via OTC Markets, a video webinar regarding the retinal screening medical device technology being developed by the Company to help prevent blindness and multiple systemic diseases, the Company’s business opportunities and the professional background

PETALUMA, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS™. He will also advise RTGN on its other corporate activities. In this capacity, specifically, he will (a) participate in